Benzinga | Jun 23, 2021 07:40AM EDT

Truist Securities Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $125

Truist Securities analyst Robyn Karnauskas maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $128 to $125.